Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b multicenter, double-blind, placebo-controlled, randomized, and dose-finding obesity or overweight clinical study of enobosarm in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide)

Next Previous
Trial Profile

Phase 2b multicenter, double-blind, placebo-controlled, randomized, and dose-finding obesity or overweight clinical study of enobosarm in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Oct 2024 According to a Veru media release, the Company will present Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss, at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.
  • 24 May 2024 According to Veru media release, data from this trial will present an update of Verus Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am to 11:25 am ET.
  • 25 Apr 2024 According to Veru media release, data from this trial will be presented at at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top